BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint

​BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency, met one co-primary endpoint.

The post BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Sunrise Group secures FDA clearance for home sleep test
SERB signs agreement to acquire Idefirix rights for $133.6m
Hospital at home: the new model of modern care
Boston Scientific invests $1.5bn for equity stake in MiRus
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us